Medication info
Rinamax Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Rinamax Sustained Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Korea Prime Pharmaceutical Co., Ltd.
Appearance
Oval-shaped sustained release tablet with P501 engraved on one side, white to almost white
Packaging
28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle
Approval status
Active

MFDS item code 202400612 · Approved 2024.03.22 · Insurance code 663608790

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Korea Prime Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used to help individuals with type 2 diabetes control their blood sugar levels. By administering linagliptin and metformin together, it complements dietary and exercise regimens to effectively manage blood glucose levels. This combination therapy aids in improving blood sugar control and has a positive impact on patients' diabetes management.

How to take

Adult dose

The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This medication should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, this medication should be swallowed whole and not split, crushed, ground, or chewed. The 5/1000 mg extended-release tablet of this medication should be taken once daily as 1 tablet per dose. Patients taking the 2.5/1000 mg extended-release tablets of this medication should take 2 tablets together once daily. 1. Patients not currently receiving metformin: The initial dose of this medication is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medication is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this medication consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this medication is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medication, the dose of this medication is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medication and periodically during treatment. No dose adjustment of this medication is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, who tolerate treatment well and have no other conditions that may increase the risk of lactic acidosis, this medication may be used with adjustment of the metformin hydrochloride dose as follows. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medication. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) falls below 45mL/min or estimated glomerular filtration rate (eGFR) falls below 45mL/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication can cause severe lactic acidosis or hypoglycemia, so immediate medical attention should be sought if these symptoms occur. Do not use this medication if you have an allergy to any of its components or have conditions such as type 1 diabetes, severe kidney dysfunction, liver dysfunction, or acute infections. Patients with impaired kidney function or the elderly should regularly monitor kidney function while using this medication, and dosage adjustments may be required if necessary. Caution is needed when taking this medication with sulfonylureas or insulin as the risk of hypoglycemia may increase, and blood sugar levels should be closely monitored. Acute pancreatitis or blistering skin lesions may occur, so if there is persistent severe abdominal pain or skin abnormalities, discontinue use and consult a doctor immediately. It is advisable to take this medication during or after meals to reduce gastrointestinal side effects. If pregnant or breastfeeding, it is recommended to avoid using this medication and consult a doctor if pregnancy is planned. This medication may interact with other drugs, so it is essential to inform your doctor or pharmacist of any current medications. If undergoing surgery or receiving iodinated contrast agents during radiological examinations, temporarily discontinue this medication and resume it only after kidney function stabilizes. This medication should be swallowed whole without chewing or breaking, and the tablet coating may be expelled in the stool, which is normal. Possible adverse reactions during treatment may include diarrhea, abdominal pain, nausea, vomiting, etc. Severely persistent symptoms should be discussed with a physician. Regular blood tests and kidney function tests during use of this medication are advisable for safety.

Side effects

  • Severe lactic acidosis
  • hypoglycemia
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption tests
  • hypoglycemic episodes
  • taste disturbance
  • cough
  • loss of appetite
Show 115 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • similar to dermatitis herpetiformis
  • severe and debilitating arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity reactions
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • shingles
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • reduced appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer's type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • hematuria
  • hypotension
  • flushing
  • fatty liver
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • dizziness
  • sensory loss
  • chest discomfort
  • myasthenia
  • nosebleed
  • oropharyngeal pain
  • speech disorder
  • epistaxis
  • vocal cord polyp
  • dyslipidemia
  • hypercholesterolemia
  • male pattern baldness
  • hyperhidrosis
  • dermatitis
  • delirium
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is best kept at room temperature between 1°C and 30°C, avoiding excessively hot or cold environments.

Appearance and packaging

Appearance

Oval-shaped sustained release tablet with P501 engraved on one side, white to almost white

Package unit

28 tablets/box [7 tablets/PTP x 4], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.